Intellia Therapeutics Inc
NASDAQ:NTLA
Intellia Therapeutics Inc
NASDAQ:NTLA
Price:
25.89 USD
-1.26%
Market Closed
Updated:
May 21, 2024
Section:
Relative Value
The Relative Value of one
NTLA
stock under the Base Case scenario is
9.61
USD.
Compared to the current market price of 25.89 USD,
Intellia Therapeutics Inc
is
Overvalued by 63%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
NTLA
Relative Value
Base Case
9.61
USD
Overvaluation 63%
Valuation Multiples
Multiples Across Competitors
NTLA Competitors Multiples
Intellia Therapeutics Inc Competitors
Intellia Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Intellia Therapeutics Inc
NASDAQ:NTLA
|
2.4B USD | 26.5 | -2.9 | -1.7 | -1.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
290.6B USD | 5.3 | 48.8 | 13.7 | 21.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.7B USD | 5.7 | 44.8 | 18.8 | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
115.2B USD | 11.3 | 28.7 | 24 | 25.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
108.8B USD | 8.3 | 28.2 | 22.8 | 25.3 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.3B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
84.6B USD | 3.1 | 174.8 | 8.8 | 11.6 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
54B USD | 10.5 | -9 | -10.1 | -9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.7B USD | 3.5 | 28.9 | 14.7 | 18.3 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.7T KRW | 17.8 | 72.3 | 44.3 | 61 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
